



Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences

April 27, 2026

CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that five abstracts have been accepted for presentation, including one oral presentation and two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, one oral presentation at TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, and one oral presentation at the 94th European Atherosclerosis Society (EAS) Congress. The Company is presenting new preclinical data, including data to support the potential of EDIT-401, its lead *in vivo* development candidate, to be a transformative therapy for people living with hyperlipidemia.

The complete list of Editas Medicine presentations is below.

American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting, May 11-15

Oral Presentation:

Title: Preclinical Development of EDIT-401, a Durable *In Vivo* CRISPR Gene Editing Therapy That Upregulates LDLR Protein to Lower LDL-C

Session Date and Time: Thursday, May 14, 3:30 p.m. – 5:00 p.m. EDT

Session Title: Gene Therapy for Cardiovascular Diseases

Presentation Room: 206AB

Final Abstract Number: 380

Poster Presentations:

Title: Pharmacokinetics and Pharmacodynamics of *In Vivo* Gene Editing Therapy for Lowering LDL-C in Mice

Session Date and Time: Thursday, May 14, 5:00 p.m. – 6:30 p.m. EDT

Session Title: Thursday Poster Reception

Presentation Room: Exhibit and Poster Hall

Final Abstract Number: 3423

Title: *In Vivo* CRISPR-based Disruption of an Important Gene Repressor Element Upregulates a Compensatory Protein to Normalize Disease-Associated Biomarkers in a Knockout Mouse Disease Model

Session Date and Time: Wednesday, May 13, 5:00 p.m. – 6:30 p.m. EDT

Session Title: Wednesday Poster Reception

Presentation Room: Exhibit and Poster Hall

Final Abstract Number: 2324

TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference, May 11-14

Oral Presentation:

Title: Transformative LDL Cholesterol Lowering *In Vivo* CRISPR Gene Editing Approach for Hyperlipidemia and Atherosclerotic Cardiovascular Disease

Session Date and Time: Wednesday, May 13, 8:30 a.m. – 9:00 a.m. EDT

Session Title: mRNA & Genome Editing: Technology & Applications

94th European Atherosclerosis Society (EAS) Congress, May 24-27

Oral Presentation:

Title: A Transformative *In Vivo* CRISPR Gene Editing Medicine Upregulates LDLR and Meaningfully Reduces LDL-C in Non-Human Primates

Session Date and Time: Monday, May 25, 3:45 p.m. – 5:15 p.m. EET/9:45 a.m. – 11:15 a.m. EDT

Session Title: New Pathways for Lipid and Lipoprotein Metabolism

Presentation Room: Nana Hall

Final Abstract Number: 159

Abstracts can be accessed on the conference websites as they become available, and the presentations will be posted on the Editas Medicine website during the conferences.

About Editas Medicine

As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative *in vivo* medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision *in vivo* gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Investor and Media Contacts:

ir@editasmed.com

media@editasmed.com



Source: Editas Medicine, Inc.